NCT01890837View on ClinicalTrials.gov

Effect of TU-100 in Patients With Irritable Bowel Syndrome (IBS)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
Irritable Bowel SyndromeDigestive System DiseasesGastrointestinal DiseasesIntestinal DiseasesAbdominal Pain
Interventions
DRUG

Daikenchuto (TU-100)

Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 2 weeks.

DRUG

Placebo

Subjects will receive daily dose of TU-100 placebo. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 2 weeks.

Trial Locations (1)

55905

Mayo Clinic, Rochester Methodist CRU, Rochester

Sponsors

Collaborators (1)

Cato Research
All Listed Sponsors
collaborator

Cato Research

INDUSTRY

lead

Tsumura USA

INDUSTRY

NCT01890837 - Effect of TU-100 in Patients With Irritable Bowel Syndrome (IBS) | Biotech Hunter | Biotech Hunter